Bad pre-holiday news from the Phase III trial with pexelizumab gave investors in Alexion Pharmaceuticals Inc. little cause to be thankful, and Wall Street took away more than a fourth of the stock's value. (BioWorld Today)

Stock-punishing news this fall about a slowdown in development of Incyte Corp''s HIV drug was followed by much happier word Monday, in the form of a potential $803 million research and licensing deal with Pfizer Inc. focused on the Phase II CCR2 antagonist program. (BioWorld Today)

Iconix Pharmaceuticals Inc.'s chemogenomics platform bagged another big-name pharma deal, this time signing up Eli Lilly and Co. to a research and license agreement described as "similar in scope" to last year's pacts with Bristol-Myers Squibb Co. and Abbott Laboratories Inc. (BioWorld Today)

To more quickly "address [the] global public health need" of a vaccine against the avian flu, Gilead Sciences Inc. and F. Hoffmann-La Roche Ltd. are ending their dispute over Tamiflu, and $62.5 million is changing hands. (BioWorld Today)